The impact of DPP-4 inhibitor on daily glucose profile and coronary plaque character in impaired glucose tolerance patients with coronary artery disease

Not Applicable

Completed

• Conditions: patients with coronary artery disease and impaired glucose tolerance (IGT)

• Registration Number: JPRN-UMIN000008620
• Lead Sponsor: Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine

Brief Summary

Vildagliptin could reduce the MAGE at 6 months and may be associated with the decreased lipid arc and increased minimum FCT of the coronary plaques in CAD patients with IGT as compared with the control group. These findings may represent its potential stabilization effect on coronary plaques, which are characteristic in this patient subset.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-08-06
• Study Completion: 2019-03-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Not provided

Exclusion Criteria

Patients meeting one of the following conditions will be excluded: 1)under treatment of diabetes, or type 1 diabetes 2)severe liver dysfunction 3)severe renal dysfunction 4)severe heart failure) (NYHA/New York Heart Association stage III or severer) 5)Malignancies or other diseases with poor prognosis 6) pregnant, lactating, and possibly pregnant women and those planning to become pregnant 7) past medical history of hypersensitivity to investigational drugs 8) judged as ineligible by clinical investigators

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in coronary plaque character analyzed by coronary angiography, intravascular ultrasound, and optical coherence tomography, and daily glucose profile analyzed by 24-hour continuous glucose monitoring system before and after 6 months treatment with vildagliptin in comparison with conventional treatment without DPP-4 inhibitor

Secondary Outcome Measures

Name	Time	Method
1)Changes in the IMT value measured by carotid arterial echography 2)Changes in HbA1c (NGSP) and 75g OGTT (glucose and insulin levels after glucose load)